Editorial: Interplay Between Epigenetic Modifiers and Transcription Factors in Driving Cancer Progression

Authors

Yongyong Yang, Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Annalisa Di Ruscio, Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA, United States.
Satoshi Inoue, Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Guocan Wang, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Shuai Gao, Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, United States.Follow

Author Type(s)

Faculty

DOI

10.3389/fonc.2023.1211537

Journal Title

Frontiers in Oncology

First Page

1211537

Document Type

Editorial

Publication Date

1-1-2023

Department

Cell Biology and Anatomy

Keywords

drug-resistance, epigenetic modulators, gene transcription, liquid-like phase separation, prostate cancer, reprogramming, super-enhancer, transcription factors

Disciplines

Medicine and Health Sciences

Recommended Citation

Yang, Y., Di Ruscio, A., Inoue, S., Wang, G., & Gao, S. (2023). Editorial: Interplay Between Epigenetic Modifiers and Transcription Factors in Driving Cancer Progression. Frontiers in Oncology, 13, 1211537. https://doi.org/10.3389/fonc.2023.1211537